Securian Asset Management Inc. Has $1.78 Million Stock Holdings in DexCom, Inc. $DXCM

Securian Asset Management Inc. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,350 shares of the medical device company’s stock after selling 253 shares during the quarter. Securian Asset Management Inc.’s holdings in DexCom were worth $1,776,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Golden State Wealth Management LLC lifted its stake in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom in the first quarter worth $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom in the first quarter worth $37,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom in the first quarter worth $40,000. Finally, Private Trust Co. NA lifted its stake in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Truist Financial reduced their price objective on shares of DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Raymond James Financial boosted their price objective on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Argus began coverage on shares of DexCom in a research note on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $96.40.

DexCom Price Performance

Shares of DexCom stock opened at $70.70 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a fifty day moving average price of $72.76 and a two-hundred day moving average price of $77.65. The company has a market cap of $27.73 billion, a PE ratio of 49.10, a price-to-earnings-growth ratio of 1.46 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm earned $0.43 EPS. The business’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.